Labcorp Holdings (LH) Expands Cancer And Liver Testing, Is It Fully Priced?
Labcorp Holdings (LH) is in focus after peer reviewed studies highlighted its Metabolic Vulnerability Index and NIS2+ blood test for liver disease ris...
Last updated: 2026-07-09 00:49:18 ET
Labcorp Holdings (LH) is in focus after peer reviewed studies highlighted its Metabolic Vulnerability Index and NIS2+ blood test for liver disease ris...
AUSTIN, Texas, July 06, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of...
In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk ...
If we don’t know the source, not only do humans remain at risk but wildlife can suffer needlessly via retaliationWhile virologists and public health...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE